Filtered By:
Drug: Bisoprolol
Countries: UK Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: June 2018Source: The Lancet Diabetes & Endocrinology, Volume 6, Issue 6Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown, The British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study GroupSummaryBackgroundIn the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did ...
Source: The Lancet Diabetes and Endocrinology - July 10, 2018 Category: Endocrinology Source Type: research

Left ventricular hypertrophy diagnosed after a stroke: a case report
ConclusionsElectrocardiogram diagnosis of left ventricular hypertrophy led to the diagnosis of apical hypertrophic cardiomyopathy in this patient. Left ventricular hypertrophy was only evident a few days after our patient suffered a stroke. The underlying mechanisms responsible for this remain unclear. Furthermore, differential diagnosis of hypertrophic cardiomyopathy should be considered in people with electrocardiogram criteria for left ventricular hypertrophy. Cardiovascular magnetic resonance imaging is an important diagnostic tool in identifying causes of left ventricular hypertrophy. Family screening should be recomm...
Source: Journal of Medical Case Reports - March 22, 2018 Category: General Medicine Source Type: research